What Can You Expect at the Premier mRNA Forum in 2025?
With 450+ active mRNA drugs populating each phase of development and the industry rapidly expanding into new disease indications, this year’s 5th mRNA-Based Therapeutics Summit returns with a refreshed, comprehensive program spotlighting key progress and new data sharing from the community.
This is your ultimate forum to take advantage of key networking opportunities, strategize your mRNA’s therapeutic potential, and successfully bring mRNA vaccines, therapeutics and new technologies towards clinical and commercial success for patients in need.
Unmissable Agenda Highlights
CEO Think Tank
On the first day of the summit, the CEO and global leaders from the field’s leading mRNA-dedicated biotechs will share their personal thoughts on the current state-of-play, pipeline strategy and decision making to set the mRNA roadmap into 2025.
Hear from:
- Alexander Zehnder, Chief Executive Officer, CureVac
Ron Phillip, Chief Executive Officer, Orbital Therapeutics - Joseph Payne, President & Chief Executive Officer, Arcturus Therapeutics
- Sophia Lugo, Chief Executive Officer, Chairman & Co-Founder, Radar Therapeutics
- Nathaniel Wang, Chief Executive Officer, Replicate Bioscience
- Priya Mande, Chief Executive Officer, RNAvate
mRNA Investor Showcase
With 500+ mRNA dedicated biopharma globally turbocharging the next wave of mRNA innovation and accelerating towards the clinic, the industry remains ripe for investment. Key investors will spotlight how the mRNA investment landscape is evolving and the capital outlook for 2025 and beyond.
Investors:
- Kristin Thompson, Investment Director at Merieux Equity Partners
- Richard Shen, Managing Director at Sedgwick Yard & Interim Chief
Executive Officer at Endotope Biosciences - Ilya Vensky, General Partner at Provisio Ventures
- David Kolesky, Principal at MPM BioImpact
Next Generation mRNA Delivery
Delivery remains the biggest bottleneck for extra-hepatic mRNA protein expression for all disease applications. This Next Generation mRNA Delivery Focus Day will delve into the latest innovations in LNP-conjugated and novel viral delivery systems beyond LNP to overcome key challenges including extra-hepatic delivery, immunogenicity, toxicity and beyond.
Hear from:
- Kinkini Roy, Associate Director – Drug Product Development at Aviceda Therapeutics
- Michelle Teplensky, Assistant Professor of Biomedical Engineering, Boston University & Scientific Founder at Flashpoint Therapeutics
- Alex Lagadinos, Head of Business Development at Mana Bio
- Ashish Kulkarni, Associate Professor of Chemical Engineering, University of Massachusetts Amherst
- Peter Berglund, Chief Scientific Officer at HDT Bio
Brand New Companies for 2025
Providing the ultimate global forum to showcase new and emerging platform technologies, 2025 brings you an all-star line-up of 30+ new global biotech entrants from novel mRNA design to delivery technologies ready to unlock the power of mRNA and transform revolutionary mRNA-based treatments for patients faster.
Divide & Conquer
The mRNA field is vast, which is why we have meticulously researched with subject matter experts to identify the key challenges facing the community, from senior scientists, to directors, to C-Level executives… the problems are different, but together we can tackle them.
By splitting into 4 tracks (Discovery, Pre-Clinical Development, Clinical Development and Manufacturing & CMC), our speakers have tailored their presentations to dive into specific challenges for those stages of development.
By sending different members of the team across the drug pipeline, you can be sure you’ve left no stone unturned.
A snapshot of key sessions featured in each track across the 2025 program:
Discovery
Discovering Novel mRNA Vaccine & Therapeutic Proof-of- Concepts to Shine Light on Promising New Applications Across Disease Indications
- Ajay Gupta, President, Chairman & Chief Executive Officer, Celestial Therapeutics
- Thomas Lyle-Temple, Chief Executive Officer, Grann Pharmaceuticals
Pre-Clinical Development
Unlocking Circular RNA Strategies for In Vivo Cell Reprogramming & Treatment of Autoimmune Diseases
- Trevor Hallam, Chief Scientific Officer, Sail Biomedicines
- Joe Bolen, Chief Scientific Officer, Orna Therapeutics
Clinical Development
Advancing Clinical Development of Personalized & Off- The-Shelf mRNA Cancer Vaccines Towards Effective & Patient Specific Treatments
- Nicholas Valiante, Chief Scientific Officer, Innovac Therapeutics
- Xiangrong Song, Chief Executive Officer & Co-Founder, WestGene Biopharma
Manufacturing & CMC
Scaling mRNA Cancer Vaccine Production & Processes With Automation Towards Better Efficiency & Speed
- Markus Bergmann, Global Program Head of Personalized Cancer Vaccines, CureVac
- Andreas Kuhn, Senior Vice President of RNA Biochemistry & CMC Development, BioNTech
Explore the Full Event Guide
- 65+ World Class Speakers
- 3 Days of Exclusive Data-Driven mRNA Content
- CEO & Investor Panel Discussions
- Exclusive Networking & Partnering Opportunities
- The World's Largest Premier Event for mRNA Dedicated Biopharma
Relive the Event Highlights
Watch our event highlights video to find out what you can look forward to.
Explore the Agenda
Hear the latest industry breakthroughs and gain exclusive insights on the mRNA innovations during our packed agenda, interactive roundtables, and new CEOs & investor panel discussions.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of mRNA biopharma deals.
Join Biopharma Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.